Preliminary studies, such as the MEDITREME trial (a related study), showed promising early efficacy, with a six-month progression-free survival rate of 62.5%.
CheckMate 9X8 is part of a broader field of study, alongside trials like AtezoTRIBE and MEDITREME, testing similar immunotherapeutic approaches. 4. Preliminary Findings & Objectives Destro 9x8
T-cell activation through "immunogenic cell death" to overcome traditional resistance to immunotherapy in MSS (microsatellite stable) colorectal cancer. 3. Preliminary studies, such as the MEDITREME trial (a
CheckMate 9X8 is a randomized phase II/III trial investigating the efficacy of combining Immune Checkpoint Inhibitors (ICIs) with standard chemotherapy in patients with Metastatic Colorectal Cancer (mCRC). 2. showed promising early efficacy